Over the last years there has been a controversy on whether the drug efflux pump P-glycoprotein (P-gp; the gene product of MDR1) influences imatinib cellular exposure and plays a clinically significant role in the resistance to Gleevec. Moreover, uptake transporters -notably the organic cation transporter hOCT1 1,2 -have been recently the focus of much attention, contributing to the heightening of the controversy on the role of efflux pumps. 3 Referring to the correspondence published this year in the Journal, 3 we present additional data on the cellular disposition of imatinib in Bcr-Abl tyrosine kinase target cell, which appears to result from a delicate equilibrium between drug uptake and efflux.
Overexpression of P-gp has been identified as a mechanism of resistance to imatinib in chronic myeloid leukemia (CML); 4 however, this has been questioned. 5, 6 The concurrent expression of other ATP-binding cassette (ABC) or solute liquid carrier (SLC) transporters, similarly mediating either influx or efflux of drug molecules, precludes in usual conditions an accurate assessment of the single contribution of one active transporter. Conversely, the specific silencing of MDR1 by RNAi provides a unique opportunity to dissect the specific contribution of P-gp to imatinib intracellular disposition. This intervention was shown to restore sensitivity to imatinib in the K562/Dox multi-drugresistant CML cell line. 7 The comparison of imatinib cellular levels in resistant and sensitive K562/Dox cell lines constitutes a key demonstration of the association between cellular sensitivity to imatinib and functional consequence of P-gp expression and inhibition, respectively. In our experiment, such cells were nucleofected with the non-viral siRNA transposon-based Sleeping Beauty vector to obtain K562/Dox-siMDR1 cells, while a non-transfected K562/Dox-si+ cell line served as control. 7 Cells were propagated and stained for P-gp by fluorescence-activated cell sorting to check for MDR1 expression, and were then seeded into 6-well plates and incubated for 2 h with 0.5-3.0 mg/ml imatinib. 7 After washing three times with cold Hank's balanced saline solution buffer, cell pellets were extracted with 1 ml MeOH/H 2 O (50:50) by vortex-mixing and ultrasonication, yielding cellular extracts assayed for their imatinib content by a validated analytical method using reversed-phase liquid chromatography coupled to tandem triple-stage quadrupole mass spectrometry (LC-MS/MS) on a TSQ Quantum (Thermo Co, San Jose, CA, USA). Imatinib-d 8 was used as internal standard. Chromatographic separation was achieved on a SymmetryShield RP8 3.5 mm column (2.1 Â 30 mm; Waters Corp, Milford, MA, USA), using MeOH þ 0.1% formic acid (A) and 10 mM ammonium acetate containing 1% AcOH (B) distributed according to the following step-wise gradient elution: 10% A-100% A, over 8 min. The mass spectrometer was operated with the electrospray ionisation source in the positive mode and using collision energy of 28 eV. Imatinib and imatinib-d 8 were monitored via selected reaction monitoring of the transition m/z 494.2 -394.2, and 502.2-394.2, respectively. This method was calibrated using matrix-matched samples prepared in diluted RPMI and blank cellular extracts, respectively. The intracellular concentrations of imatinib were calculated with a cell number of 900,000 in each well, assuming a cell volume of 0.4 pl.
The results highlight the striking differences (4-to 9-fold; Figure 1 and Table 1 ) in intracellular concentration values of imatinib as a result of RNAi-mediated MDR1 expression knockdown, with imatinib accumulating to a much higher extent in the knocked-down cells. Intra-/extra-cellular (IC/EC) ratio is significantly affected by phenotype (Po0.05; two-way ANOVA), but not by incubation concentration (Table 1) . Moreover, abrogating specifically P-gp-mediated efflux in vitro confirms the remarkable functional contribution of uptake transporters in the cellular accumulation of imatinib, with mean IC/EC ratio values reaching 250-300 (compared with 30-50 for non-siRNA transfected cells, Table 1 ). Accumulation has also been observed in vivo, albeit to a lesser extent, with an average 8-fold ratio. 8 The difference in the measured IC/EC ratios in vitro and in vivo (30-50 vs 8) is probably explained to some extent by the different cell types considered (i.e., K562 and PBMCs, respectively), and by the absence or presence of plasma carriers such as a 1 -acid glycoprotein 8 in the extracellular medium. However, the relative changes -rather than absolute values -of IC/EC ratios determined in P-gpÀ and P-gp þ cells are of interest in our experimental design. This type of experiment enables for the first time a direct estimate of the specific contribution of one Intracellular accumulation of imatinib at incubation concentrations of 1, 3 and 6 mM (i.e., 0.5, 1.5 and 3 mg/ml), according to the cell phenotype after MDR1 gene expression silencing.
transporter among the various efflux and influx carriers involved in the cellular trafficking of imatinib in vitro.
Our analysis thus clearly confirms that the restoration of imatinib sensitivity observed in the imatinib-resistant CML cell lines K562/Dox subjected to MDR1 gene silencing 7 is the result of a marked increase in imatinib intracellular disposition. This is in agreement with the observation of Mahon et al., 4 but not with the conclusions of Ferrao et al. 5 and Zong et al. 6 concerning the role played by MDR1 in imatinib resistance. In the Ferrao study, 5 however, the effect of verapamil on the hOCT1 transporter, or the expression level thereof, may have represented a confounding factor. In the study of Zong et al., 6 the validity of the murine model used has already been debated. 3 In fact, Zong et al. suggested that the discrepancies between various experiments are explained by redundant efflux mechanism of imatinib. 3 We provide here additional evidences that imatinib cellular disposition has to be considered on a wide perspective, integrating not only efflux, but also influx transporters, which are critical determinants of imatinib intracellular availability, and which probably condition in part resistance to the drug. This is supported by the recent findings that the expression level of hOCT1, 2 or the ex vivo drug uptake, 1 in CML patients represents prognostic indices for imatinib response. Such observations are not incompatible with the restoration of sensitivity by MDR1 inhibition observed by Rumpold et al. the increased intracellular levels of imatinib in doxorubicinselected K562 cells. 1 Their finding is consistent with the previously reported concept that imatinib is a substrate for P-glycoprotein (P-gp), 2, 3 and rules out other possibilities that could lead to restoration of imatinib sensitivity. However, we found that specific elimination of P-gp expression in the Table 1 Concentration of imatinib in P-gp+ and P-gpÀ (MDR1-RNAi knockdown) cells at various imatinib incubation levels Phenotype Incubation medium (mg/ml) Intracell (mg/ml) Extracell (mg/ml) Intra/extracell ratio 
